TGTX Stock Price Prediction

Analysis and Insights

Fundamental Analysis:

TG Therapeutics (TGTX) has shown strong performance recently, driven by the success of its product Briumvi, which saw a 200% year-over-year increase in sales to $313 million. The company is targeting $540 million in sales for this year, indicating high growth potential. Earnings estimates for the upcoming quarter have been revised 127.5% higher, suggesting strong investor confidence.

Technical Analysis:

The stock is currently trading at $40.94 with a bullish trend. Key technical indicators include:

• RSI (6-period): 79.33, indicating overbought conditions but still in an uptrend.
• MACD: Positive at 2.04, showing strong upward momentum.
• Fibonacci Levels: Resistance at $40.82 and $43.55, with support at $36.40.

Options Activity:

Bullish options activity has been observed, with 2,450 calls traded and increasing implied volatility to 63.04%. This indicates strong investor interest ahead of earnings on May 8th.

Conclusion:

Given the strong fundamentals, positive earnings revisions, and bullish options activity, the stock is expected to continue its upward trend. However, the overbought RSI suggests a potential short-term pullback. The next resistance level at $43.55 is a key target.

Prediction: The stock price is expected to reach $43.20 in the next trading week. Buy recommendation, as the overall trend remains bullish despite minor corrections.